LDE225B + Vehicle
Phase 2/3Withdrawn 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
— → —
NCT ID
NCT03070691About LDE225B + Vehicle
LDE225B + Vehicle is a phase 2/3 stage product being developed by Novartis for Basal Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03070691. Target conditions include Basal Cell Carcinoma.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03070691 | Phase 2/3 | Withdrawn |
Competing Products
20 competing products in Basal Cell Carcinoma